These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35482553)

  • 21. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
    Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
    Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B
    Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrine suppresses cell growth of diffuse large B-cell lymphoma via inhibiting CaMKIIγ/c-Myc/CDK6 signaling pathway.
    Gu J; Wang X; Zhang L; Xiang J; Li J; Chen Z; Zhang Y; Chen J; Shen J
    BMC Complement Med Ther; 2021 Jun; 21(1):163. PubMed ID: 34088288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.
    Mohammed AA; Rashed HE; Abdelrahman AE; Obaya AA; Toam M; Abdel Nour HM; Abdelhamid MI; Elsayed FM
    Asian Pac J Cancer Prev; 2019 May; 20(5):1463-1470. PubMed ID: 31127909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement.
    Liu L; Mo W; Chen M; Qu Y; Wang P; Liang Y; Yan X
    BMC Cancer; 2024 Jun; 24(1):761. PubMed ID: 38918775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral immune cell profiling of double-hit lymphoma by mass cytometry.
    Lei T; Wu G; Xu Y; Zhuang W; Lu J; Han S; Zhuang Y; Dong X; Yang H
    BMC Cancer; 2023 Feb; 23(1):184. PubMed ID: 36823603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
    Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
    Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double hit and double expressors in lymphoma: Definition and treatment.
    Riedell PA; Smith SM
    Cancer; 2018 Dec; 124(24):4622-4632. PubMed ID: 30252929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
    Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
    Kim H; Kim HJ; Kim SH
    Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
    Li S; Seegmiller AC; Lin P; Wang XJ; Miranda RN; Bhagavathi S; Medeiros LJ
    Mod Pathol; 2015 Feb; 28(2):208-17. PubMed ID: 25103070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
    Gordon MJ; Westin JR
    Leuk Lymphoma; 2022 May; 63(5):1034-1044. PubMed ID: 34842019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
    Sermer D; Bobillo S; Dogan A; Zhang Y; Seshan V; Lavery JA; Batlevi C; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Palomba ML; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A
    Blood Adv; 2020 Jul; 4(14):3382-3390. PubMed ID: 32722781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.
    Huang W; Medeiros LJ; Lin P; Wang W; Tang G; Khoury J; Konoplev S; Yin CC; Xu J; Oki Y; Li S
    Mod Pathol; 2018 Sep; 31(9):1470-1478. PubMed ID: 29785017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.
    Liu Y; Azizian NG; Dou Y; Pham LV; Li Y
    J Hematol Oncol; 2019 Nov; 12(1):119. PubMed ID: 31752970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.